Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study
Open Access
- 24 March 2022
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 78, 103962
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2019YFC1710400, 2019YFC1710403)
This publication has 57 references indexed in Scilit:
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity OutcomesJAMA, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2020
- Analysis of articles directly related to randomized trials finds poor protocol availability and inconsistent linking of articlesJournal of Clinical Epidemiology, 2020
- Data-sharing recommendations in biomedical journals and randomised controlled trials: an audit of journals following the ICMJE recommendationsBMJ Open, 2020
- Reporting quality and adherence of randomized controlled trials about statins and/or fibrates for diabetic retinopathy to the CONSORT checklistTrials, 2019
- Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal EditorsNew England Journal of Medicine, 2017
- Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trialsInternational Journal of Surgery, 2012
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized TrialsAnnals of Internal Medicine, 2010